Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

DOLUTEGRAVIR

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (J05A, J05AJ) — coverage varies; not interchangeable

  • Cabotegravir (Apretude): general benefit
  • Raltegravir (Isentress): general benefit
  • Abacavir + lamivudine + zidovudine (Trizivir): general benefit
  • Abacavir (Ziagen): general benefit
  • Abacavir + lamivudine (Kivexa): general benefit
  • Acyclovir (Zovirax): general benefit, Not a benefit

45 more in the class list below

PMS-Dolutegravir · DIN 02556782 · 50mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PMS-Dolutegravir · DIN 02556782 Manufacturer: Pharmascience Inc.; listing date 2026-06-30 Health Canada: Marketed since 2026-04-29 · brand PMS-DOLUTEGRAVIR · ATC J05AJ03 DOLUTEGRAVIR · form Tablet · route Oral · ingredients DOLUTEGRAVIR (DOLUTEGRAVIR SODIUM) 50 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-Dolutegravir: Formulary list price $17.6525/unit (unit not stated in source; not the patient's cost)

Ministry pays: $17.6525 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106017 · Verify on the e-Formulary ↗ (DIN 02556782)

Source record
DIN 02556782: PMS-Dolutegravir Raw flags: sec3=Y Item: 081800373; group id 73; item number 0141; lccId None; manufacturer id PMS Source form: Tab; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $17.6525; ministry $17.6525 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02556782 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106017
Interchangeable products
Tivicay · DIN 02414945 · $17.6525
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02556782
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Tivicay · DIN 02414945 · 50mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

ViiV Supports Patient Support Program

Manufacturer assistance may reduce out-of-pocket costs. If this ViiV medication is prescribed and cost is a barrier, ask your pharmacist about ViiV Supports. Canadian residence and a valid prescription are required; the program assesses financial need.

1-855-525-5300 · Canadian ViiV support and registration

Manufacturer assistance is not subtracted from public estimates. Final out-of-pocket cost is not established.

Assistance conditions and dated sources

The amount, maximum, duration and detailed financial eligibility have not been confirmed. Assistance is not guaranteed.

A Trillium deductible interaction is not stated in the public materials checked. Ask ViiV Supports and the pharmacist to confirm. No assistance is subtracted from public estimates.

Ask your pharmacist about ViiV Supports, or call the Canadian program before registering. It can help check public and private coverage options.

A valid prescription for a participating ViiV product is required. A product match does not establish the reason it was prescribed or financial eligibility.

The current welcome page states Monday to Friday, 8 am to 8 pm EST; confirm availability with the program.

Possible temporary financial assistance at the manufacturer's discretion; eligibility is not guaranteed and support may change or end.

“The program offers reimbursement navigation services to assist patients in obtaining public and/or private coverage.” June 2026, code PM-CA-HVX-WCNT-260001; accessed 2026-09-18

“Your eligibility in the Program is not guaranteed” Undated current linked terms, pages 1-2; accessed 2026-09-18

1 brand, same coverage
Tivicay · DIN 02414945 Manufacturer: ViiV Healthcare ULC; listing date 2015-04-30 Health Canada: Marketed since 2013-11-08 · brand TIVICAY · ATC J05AJ03 DOLUTEGRAVIR · form Tablet · route Oral · ingredients DOLUTEGRAVIR (DOLUTEGRAVIR SODIUM) 50 MG · company Viiv healthcare ulc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $17.6525 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89957 · Verify on the e-Formulary ↗ (DIN 02414945)

Source record
DIN 02414945: Tivicay Raw flags: sec3=Y Item: 081800373; group id 73; item number 0141; lccId None; manufacturer id VIH Source form: Tab; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $23.9840; ministry $17.6525 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02414945 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89957
Interchangeable products
PMS-Dolutegravir · DIN 02556782 · $17.6525
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02414945
Shortage record checked 2026-09-13T08:10:21.292534+00:00

DOLUTEGRAVIR & ABACAVIR & LAMIVUDINE

All products: general benefit

Other products in the same Health Canada class (J05A, J05AJ) — coverage varies; not interchangeable

  • Cabotegravir (Apretude): general benefit
  • Raltegravir (Isentress): general benefit
  • Abacavir + lamivudine + zidovudine (Trizivir): general benefit
  • Abacavir (Ziagen): general benefit
  • Abacavir + lamivudine (Kivexa): general benefit
  • Acyclovir (Zovirax): general benefit, Not a benefit

45 more in the class list below

Triumeq · DIN 02430932 · 50mg & 600mg & 300mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

ViiV Supports Patient Support Program

Manufacturer assistance may reduce out-of-pocket costs. If this ViiV medication is prescribed and cost is a barrier, ask your pharmacist about ViiV Supports. Canadian residence and a valid prescription are required; the program assesses financial need.

1-855-525-5300 · Canadian ViiV support and registration

Manufacturer assistance is not subtracted from public estimates. Final out-of-pocket cost is not established.

Assistance conditions and dated sources

The amount, maximum, duration and detailed financial eligibility have not been confirmed. Assistance is not guaranteed.

A Trillium deductible interaction is not stated in the public materials checked. Ask ViiV Supports and the pharmacist to confirm. No assistance is subtracted from public estimates.

Ask your pharmacist about ViiV Supports, or call the Canadian program before registering. It can help check public and private coverage options.

A valid prescription for a participating ViiV product is required. A product match does not establish the reason it was prescribed or financial eligibility.

The current welcome page states Monday to Friday, 8 am to 8 pm EST; confirm availability with the program.

Possible temporary financial assistance at the manufacturer's discretion; eligibility is not guaranteed and support may change or end.

“The program offers reimbursement navigation services to assist patients in obtaining public and/or private coverage.” June 2026, code PM-CA-HVX-WCNT-260001; accessed 2026-09-18

“Your eligibility in the Program is not guaranteed” Undated current linked terms, pages 1-2; accessed 2026-09-18

No interchangeable product listed in the Ontario extract
Triumeq · DIN 02430932 Manufacturer: ViiV Healthcare ULC; listing date 2015-05-28 Health Canada: Marketed since 2014-10-22 · brand TRIUMEQ · ATC J05AR13 LAMIVUDINE, ABACAVIR AND DOLUTEGRAVIR, J05AR13 LAMIVUDINE, ABACAVIR AND DOLUTEGRAVIR · form Tablet · route Oral · ingredients DOLUTEGRAVIR (DOLUTEGRAVIR SODIUM) 50 MG, ABACAVIR (ABACAVIR SULFATE) 600 MG, LAMIVUDINE 300 MG · company Viiv healthcare ulc · schedule Prescription
Check this DIN again · Health Canada product record

Triumeq: Formulary list price $53.1353/unit (unit not stated in source; not the patient's cost)

Ministry pays: $53.1353 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91536 · Verify on the e-Formulary ↗ (DIN 02430932)

Source record
DIN 02430932: Triumeq Raw flags: sec3=Y Item: 081800374; group id 74; item number 0142; lccId None; manufacturer id VIH Source form: Tab; strength: 50mg & 600mg & 300mg Recorded listing: General benefit Source prices (unrounded): $53.1353; ministry $53.1353 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02430932 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91536
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02430932
Shortage record checked 2026-09-13T08:10:21.292534+00:00

DOLUTEGRAVIR & RILPIVIRINE

All products: general benefit

Other products in the same Health Canada class (J05A, J05AJ) — coverage varies; not interchangeable

  • Cabotegravir (Apretude): general benefit
  • Raltegravir (Isentress): general benefit
  • Abacavir + lamivudine + zidovudine (Trizivir): general benefit
  • Abacavir (Ziagen): general benefit
  • Abacavir + lamivudine (Kivexa): general benefit
  • Acyclovir (Zovirax): general benefit, Not a benefit

45 more in the class list below

Juluca · DIN 02475774 · 50mg & 25mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

ViiV Supports Patient Support Program

Manufacturer assistance may reduce out-of-pocket costs. If this ViiV medication is prescribed and cost is a barrier, ask your pharmacist about ViiV Supports. Canadian residence and a valid prescription are required; the program assesses financial need.

1-855-525-5300 · Canadian ViiV support and registration

Manufacturer assistance is not subtracted from public estimates. Final out-of-pocket cost is not established.

Assistance conditions and dated sources

The amount, maximum, duration and detailed financial eligibility have not been confirmed. Assistance is not guaranteed.

A Trillium deductible interaction is not stated in the public materials checked. Ask ViiV Supports and the pharmacist to confirm. No assistance is subtracted from public estimates.

Ask your pharmacist about ViiV Supports, or call the Canadian program before registering. It can help check public and private coverage options.

A valid prescription for a participating ViiV product is required. A product match does not establish the reason it was prescribed or financial eligibility.

The current welcome page states Monday to Friday, 8 am to 8 pm EST; confirm availability with the program.

Possible temporary financial assistance at the manufacturer's discretion; eligibility is not guaranteed and support may change or end.

“The program offers reimbursement navigation services to assist patients in obtaining public and/or private coverage.” June 2026, code PM-CA-HVX-WCNT-260001; accessed 2026-09-18

“Your eligibility in the Program is not guaranteed” Undated current linked terms, pages 1-2; accessed 2026-09-18

No interchangeable product listed in the Ontario extract
Juluca · DIN 02475774 Manufacturer: ViiV Healthcare ULC; listing date 2019-04-30 Health Canada: Marketed since 2018-06-04 · brand JULUCA · ATC J05AR21 DOLUTEGRAVIR AND RILPIVIRINE, J05AR21 DOLUTEGRAVIR AND RILPIVIRINE · form Tablet · route Oral · ingredients DOLUTEGRAVIR (DOLUTEGRAVIR SODIUM) 50 MG, RILPIVIRINE (RILPIVIRINE HYDROCHLORIDE) 25 MG · company Viiv healthcare ulc · schedule Prescription
Check this DIN again · Health Canada product record

Juluca: Formulary list price $41.7120/unit (unit not stated in source; not the patient's cost)

Ministry pays: $41.7120 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96645 · Verify on the e-Formulary ↗ (DIN 02475774)

Source record
DIN 02475774: Juluca Raw flags: sec3=Y Item: 081800392; group id 75; item number 0143; lccId None; manufacturer id VIH Source form: Tab; strength: 50mg & 25mg Recorded listing: General benefit Source prices (unrounded): $41.7120; ministry $41.7120 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02475774 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96645
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02475774
Shortage record checked 2026-09-13T08:10:21.292534+00:00

DOLUTEGRAVIR SODIUM/LAMIVUDINE

All products: general benefit

Other products in the same Health Canada class (J05A, J05AJ) — coverage varies; not interchangeable

  • Cabotegravir (Apretude): general benefit
  • Raltegravir (Isentress): general benefit
  • Abacavir + lamivudine + zidovudine (Trizivir): general benefit
  • Abacavir (Ziagen): general benefit
  • Abacavir + lamivudine (Kivexa): general benefit
  • Acyclovir (Zovirax): general benefit, Not a benefit

45 more in the class list below

Dovato · DIN 02491753 · 50mg & 300mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

ViiV Supports Patient Support Program

Manufacturer assistance may reduce out-of-pocket costs. If this ViiV medication is prescribed and cost is a barrier, ask your pharmacist about ViiV Supports. Canadian residence and a valid prescription are required; the program assesses financial need.

1-855-525-5300 · Canadian ViiV support and registration

Manufacturer assistance is not subtracted from public estimates. Final out-of-pocket cost is not established.

Assistance conditions and dated sources

The amount, maximum, duration and detailed financial eligibility have not been confirmed. Assistance is not guaranteed.

A Trillium deductible interaction is not stated in the public materials checked. Ask ViiV Supports and the pharmacist to confirm. No assistance is subtracted from public estimates.

Ask your pharmacist about ViiV Supports, or call the Canadian program before registering. It can help check public and private coverage options.

A valid prescription for a participating ViiV product is required. A product match does not establish the reason it was prescribed or financial eligibility.

The current welcome page states Monday to Friday, 8 am to 8 pm EST; confirm availability with the program.

Possible temporary financial assistance at the manufacturer's discretion; eligibility is not guaranteed and support may change or end.

“The program offers reimbursement navigation services to assist patients in obtaining public and/or private coverage.” June 2026, code PM-CA-HVX-WCNT-260001; accessed 2026-09-18

“Your eligibility in the Program is not guaranteed” Undated current linked terms, pages 1-2; accessed 2026-09-18

No interchangeable product listed in the Ontario extract
Dovato · DIN 02491753 Manufacturer: ViiV Healthcare ULC; listing date 2020-01-31 Health Canada: Marketed since 2019-09-09 · brand DOVATO · ATC J05AR25 LAMIVUDINE AND DOLUTEGRAVIR, J05AR25 LAMIVUDINE AND DOLUTEGRAVIR · form Tablet · route Oral · ingredients LAMIVUDINE 300 MG, DOLUTEGRAVIR (DOLUTEGRAVIR SODIUM) 50 MG · company Viiv healthcare ulc · schedule Prescription
Check this DIN again · Health Canada product record

Dovato: Formulary list price $36.4157/unit (unit not stated in source; not the patient's cost)

Ministry pays: $36.4157 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98173 · Verify on the e-Formulary ↗ (DIN 02491753)

Source record
DIN 02491753: Dovato Raw flags: sec3=Y Item: 081800397; group id 76; item number 0144; lccId None; manufacturer id VIH Source form: Tab; strength: 50mg & 300mg Recorded listing: General benefit Source prices (unrounded): $36.4157; ministry $36.4157 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02491753 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98173
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02491753
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (08:18 Antivirals) and how they are covered

Matched class: 08:18 Antivirals

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ABACAVIR & LAMIVUDINE & ZIDOVUDINE, ABACAVIR SULFATE, ABACAVIR SULFATE & LAMIVUDINE, BICTEGRAVIR SODIUM/EMTRICITABINE/TENOFOVIR ALAFENAMIDE HEMIFUMARATE, CABOTEGRAVIR, CABOTEGRAVIR & RILPIVIRINE, COBICISTAT & ELVITEGRAVIR & EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE, DARUNAVIR & COBICISTAT, DARUNAVIR & COBICISTAT & EMTRICITABINE & TENOFOVIR ALAFENAMIDE, DELAVIRDINE MESYLATE, DORAVIRINE, DORAVIRINE/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ/TENOFOVIR DISOPROXIL FUMARATE/EMTRICITABINE, ELVITEGRAVIR & COBICISTAT & EMTRICITABINE & TENOFOVIR ALAFENAMIDE, EMTRICITABINE & RILPIVIRINE HCL & TENOFOVIR ALAFENAMIDE HEMIFUMARATE, EMTRICITABINE & RILPIVIRINE HCL & TENOFOVIR DISOPROXIL, EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE, ETRAVIRINE, FOSAMPRENAVIR CALCIUM, GANCICLOVIR SODIUM, LAMIVUDINE & ZIDOVUDINE, LOPINAVIR & RITONAVIR, MARAVIROC, NELFINAVIR MESYLATE, RALTEGRAVIR POTASSIUM, RILPIVIRINE HYDROCHLORIDE, RITONAVIR Some products covered without a code (check the product listing): ACYCLOVIR, ATAZANAVIR SULFATE, DARUNAVIR, EFAVIRENZ, LAMIVUDINE, NEVIRAPINE, VALACYCLOVIR 08:18 Antivirals

CABOTEGRAVIR

· 3 products · General benefit · strengths: 200mg/mL, 30mg · Inj Sol-ER Susp 3mL Vial Kit Pk, Tab

RALTEGRAVIR POTASSIUM

· 2 products · General benefit · strengths: 400mg, 600mg · Tab

ABACAVIR & LAMIVUDINE & ZIDOVUDINE

· 2 products · General benefit · strengths: 300mg & 150mg & 300mg · Tab

ABACAVIR SULFATE

· 4 products · General benefit · strengths: 20mg/mL, 300mg · O/L, Tab

ABACAVIR SULFATE & LAMIVUDINE

· 7 products · General benefit · strengths: 600mg & 300mg · Tab

ACYCLOVIR

· 15 products · Listed, not a benefit (2), General benefit (13) · strengths: 200mg, 400mg, 800mg · Tab

ATAZANAVIR SULFATE

· 12 products · General benefit (8), Off-Formulary Interchangeable, not an ODB benefit (4) · strengths: 150mg, 200mg, 300mg · Cap

BICTEGRAVIR SODIUM/EMTRICITABINE/TENOFOVIR ALAFENAMIDE HEMIFUMARATE

· 1 products · General benefit · strengths: 50mg & 200mg & 25mg · Tab

CABOTEGRAVIR & RILPIVIRINE

· 2 products · General benefit · strengths: 200mg/mL & 300mg/mL · Inj Sol-2mL Kit, Inj Sol-3mL Kit

COBICISTAT & ELVITEGRAVIR & EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE

· 1 products · General benefit · strengths: 150mg & 150mg & 200mg & 300mg · Tab

DARUNAVIR

· 8 products · Listed, not a benefit (2), General benefit (6) · strengths: 600mg, 800mg · Tab

DARUNAVIR & COBICISTAT

· 1 products · General benefit · strengths: 800mg & 150mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:18 and 39 more
Full class listing Related classes: 08:08 Anthelmintics, 08:12 Antibiotics, 08:14 Antifungals, 08:16 Antitubercular Agents, 08:20 Plasmodicides (Antimalarials), 08:24 Sulfonamides, 08:30 Antiprotozoals, 08:32 Trichomonacides, 08:36 Urinary Anti-Infectives, 08:40 Miscellaneous Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 Indications TIVICAY, in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (HIV-1) infection in adults and in INSTI-naïve pediatric patients aged 4 weeks and older and weighing at least 3 kg. 1.1 Pediatrics Pediatrics (aged less than 4 weeks or weighing less than 3 kg or INSTI-experienced): Safety and efficacy of TIVICAY have not been established in children aged less than 4 weeks or weighing less than 3 kg or who are INSTI-experienced with documented or clinical suspected resistance to other INSTIs. 1.2 Geriatrics Geriatrics (≥ 65 years of age): Clinical studies of TIVICAY did not include sufficient numbers of patients aged 65 years and older to determine whether they respond differently from adult patients < 65 years of age. https://pdf.hres.ca/dpd_pm/00082179.PDF PM date: 2025-10-24 Source product: TIVICAY; DIN 02414945; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 Indications TRIUMEQ (dolutegravir, abacavir, and lamivudine) is indicated for the treatment of Human Immunodeficiency Virus (HIV-1) infection in adults and adolescents aged 12 years and older and weighing at least 40 kg. 1.1 Pediatrics Pediatrics (<12 years of age and weighing less than 40 kg): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use <12 years of age and weighing less than 40 kg. Pediatrics (>12 to 18 years of age and weighing at least 40 kg): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of TRIUMEQ in pediatric patients >12 to 18 years of age and weighing at least 40 kg has been established. Therefore, Health Canada has authorized an indication for pediatric use for >12 to 18 years of age and weighing at least 40 kg. 1.2 Geriatrics Geriatrics (≥65 years of age): Clinical studies of TRIUMEQ did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. https://pdf.hres.ca/dpd_pm/00082178.PDF PM date: 2025-10-24 Source product: TRIUMEQ; DIN 02430932; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 Indications JULUCA (dolutegravir/rilpivirine) is indicated as a complete regimen to replace the current antiretroviral regimen for: • the treatment of human immunodeficiency virus (HIV-1) infection in adults who are virologically stable and suppressed (HIV-1 RNA less than 50 copies per mL). 1.1 Pediatrics Pediatrics (< 18 years of age): Safety and efficacy of JULUCA have not been established in pediatric patients less than 18 years of age. 1.2 Geriatrics Geriatrics (≥ 65 years of age): Clinical studies of JULUCA did not include sufficient numbers of patients aged 65 years and older to determine whether they respond differently from adult patients < 65 years of age. https://pdf.hres.ca/dpd_pm/00082175.PDF PM date: 2025-10-24 Source product: JULUCA; DIN 02475774; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 Indications DOVATO (dolutegravir and lamivudine) is indicated as a complete regimen for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents 12 years of age and older and weighing at least 40 kg. 1.1 Pediatrics Pediatrics (<18 years of age): Safety and efficacy of DOVATO in pediatric patients less than 12 years of age have not been established. There are no clinical study data with DOVATO in the adolescent population. The safety and efficacy of DOVATO in adolescents 12 years of age and older, and weighing at least 40 kg, is supported by the clinical data from studies of dolutegravir or lamivudine as single agents in combination with other antiretroviral agents in adolescents, and also by the clinical data from studies with dolutegravir in combination with lamivudine in adults (see 14 Clinical Trials, Adolescents). 1.2 Geriatrics Geriatrics (≥ 65 years of age): Clinical studies of DOVATO did not include sufficient numbers of patients aged 65 years and older to determine whether they respond differently from adult patients < 65 years of age. https://pdf.hres.ca/dpd_pm/00082174.PDF PM date: 2025-10-24 Source product: DOVATO; DIN 02491753; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.